

# Tuberculosis - Pipeline Review, H1 2020

<https://marketpublishers.com/r/T933ED09586EN.html>

Date: May 2020

Pages: 405

Price: US\$ 2,000.00 (Single User License)

ID: T933ED09586EN

## Abstracts

Tuberculosis - Pipeline Review, H1 2020

### SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Tuberculosis – Pipeline Review, H1 2020, provides an overview of the Tuberculosis (Infectious Disease) pipeline landscape.

Tuberculosis, commonly known as TB, is a bacterial infection that can spread through the lymph nodes and bloodstream to any organ in body. It is most often found in the lungs. The symptoms of tuberculosis range from no symptoms (latent tuberculosis) to symptoms of active disease. Symptoms include overall sensation of feeling unwell; cough, possibly with bloody mucus, fatigue, shortness of breath, weight loss and pain in the chest.

### REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Tuberculosis – Pipeline Review, H1 2020, provides comprehensive information on the therapeutics under development for Tuberculosis (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Tuberculosis (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Tuberculosis and features dormant and discontinued projects. The guide covers therapeutics under Development by

Companies/Universities/Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 2, 5, 12, 8, 1, 59, 39 and 4 respectively. Similarly, the Universities portfolio in Pre-Registration, Phase III, Phase II, Phase I, Preclinical and Discovery stages comprises 1, 1, 4, 6, 35 and 34 molecules, respectively.

Tuberculosis (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

**Note:** Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

## SCOPE

The pipeline guide provides a snapshot of the global therapeutic landscape of Tuberculosis (Infectious Disease).

The pipeline guide reviews pipeline therapeutics for Tuberculosis (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.

The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

The pipeline guide reviews key companies involved in Tuberculosis (Infectious Disease) therapeutics and enlists all their major and minor projects.

The pipeline guide evaluates Tuberculosis (Infectious Disease) therapeutics

based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

The pipeline guide reviews latest news related to pipeline therapeutics for Tuberculosis (Infectious Disease)

## **REASONS TO BUY**

Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

Find and recognize significant and varied types of therapeutics under development for Tuberculosis (Infectious Disease).

Classify potential new clients or partners in the target demographic.

Develop tactical initiatives by understanding the focus areas of leading companies.

Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

Formulate corrective measures for pipeline projects by understanding Tuberculosis (Infectious Disease) pipeline depth and focus of Indication therapeutics.

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.



## Contents

Introduction

Tuberculosis - Overview

Tuberculosis - Therapeutics Development

Tuberculosis - Therapeutics Assessment

Tuberculosis - Companies Involved in Therapeutics Development

Tuberculosis - Drug Profiles

Tuberculosis - Dormant Projects

Tuberculosis - Discontinued Products

Tuberculosis - Product Development Milestones

Appendix

## List Of Tables

### LIST OF TABLES

Number of Products under Development for Tuberculosis, H1 2020

Number of Products under Development by Companies, H1 2020

Number of Products under Development by Companies, H1 2020 (Contd..1), H1 2020

Number of Products under Development by Companies, H1 2020 (Contd..2), H1 2020

Number of Products under Development by Companies, H1 2020 (Contd..3), H1 2020

Number of Products under Development by Companies, H1 2020 (Contd..4), H1 2020

Number of Products under Development by Universities/Institutes, H1 2020

Number of Products under Development by Universities/Institutes, H1 2020 (Contd..1),  
H1 2020

Number of Products under Development by Universities/Institutes, H1 2020 (Contd..2),  
H1 2020

Number of Products under Development by Universities/Institutes, H1 2020 (Contd..3),  
H1 2020

Products under Development by Companies, H1 2020

Products under Development by Universities/Institutes, H1 2020

Products under Development by Universities/Institutes, H1 2020 (Contd..1), H1 2020

Products under Development by Universities/Institutes, H1 2020 (Contd..2), H1 2020

Products under Development by Universities/Institutes, H1 2020 (Contd..3), H1 2020

Products under Development by Universities/Institutes, H1 2020 (Contd..4), H1 2020

Number of Products by Stage and Target, H1 2020

Number of Products by Stage and Target, H1 2020 (Contd..1), H1 2020

Number of Products by Stage and Target, H1 2020 (Contd..2), H1 2020

Number of Products by Stage and Mechanism of Action, H1 2020

Number of Products by Stage and Mechanism of Action, H1 2020 (Contd..1), H1 2020

Number of Products by Stage and Mechanism of Action, H1 2020 (Contd..2), H1 2020

Number of Products by Stage and Route of Administration, H1 2020

Number of Products by Stage and Molecule Type, H1 2020

Tuberculosis - Pipeline by Abera Bioscience AB, H1 2020

Tuberculosis - Pipeline by AGILeBiotics BV, H1 2020

Tuberculosis - Pipeline by Akshaya Bio Inc, H1 2020

Tuberculosis - Dormant Projects, H1 2020

Tuberculosis - Discontinued Products, H1 2020

## List Of Figures

### LIST OF FIGURES

Number of Products under Development for Tuberculosis, H1 2020  
Number of Products under Development by Companies, H1 2020  
Number of Products under Development by Universities/Institutes, H1 2020  
Number of Products by Top 10 Targets, H1 2020  
Number of Products by Stage and Top 10 Targets, H1 2020  
Number of Products by Top 10 Mechanism of Actions, H1 2020  
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2020  
Number of Products by Top 10 Routes of Administration, H1 2020  
Number of Products by Stage and Top 10 Routes of Administration, H1 2020  
Number of Products by Top 10 Molecule Types, H1 2020  
Number of Products by Stage and Top 10 Molecule Types, H1 2020

### COMPANIES MENTIONED

Abera Bioscience AB  
AGILeBiotics BV  
Akshaya Bio Inc  
AN2 Therapeutics Inc  
Archivel Farma SL  
AstraZeneca Plc  
Austrianni GmbH  
BioLingus AG  
BioNTech SE  
Bioversys AG  
Bristol-Myers Squibb Co  
CanSino Biologics Inc  
Chongqing Zhifei Biological Products Co Ltd  
Collaborations Pharmaceuticals Inc  
Consegna Pharma Inc  
Crestone Inc  
Daiichi Sankyo Co Ltd  
Demuris Ltd  
Eisai Co Ltd  
Eli Lilly and Co  
Ena Therapeutics Pty Ltd

Enyo Pharma SA  
EpiVax Inc  
Evotec SE  
Faron Pharmaceuticals Oy  
Gamaleya Federal Research Center of Epidemiology and Microbiology  
GangaGen Inc  
GC Pharma  
GlaxoSmithKline Plc  
Globeimmune Inc  
Greffex Inc  
Guangdong Zhongsheng Pharmaceutical Co Ltd  
HanaVax Inc  
Hsiri Therapeutics LLC  
Immodulon Therapeutics Ltd  
Immunitor Inc  
ImmunoBiology Ltd  
Innovare R & D SA De CV  
Johnson & Johnson  
Kolmar Pharma Co Ltd  
L2 Diagnostics LLC  
LegoChem Biosciences Inc  
Matinas BioPharma Holdings Inc  
Merck & Co Inc  
MetalloPharm LLC  
Microbiotix Inc  
Mycosynthetix Inc  
Nearmedic Plus Ltd  
Novartis AG  
NovoBiotic Pharmaceuticals LLC  
NTxBio LLC  
Opal Biosciences Ltd  
Otsuka Holdings Co Ltd  
Otsuka Pharmaceutical Co Ltd  
Pai Life Sciences Inc  
Palisades Therapeutics  
Pathens Inc  
PDS Biotechnology Corp  
PeptiDream Inc  
Pfizer Inc



Pharmapraxix  
ProCrysta Biologix Inc  
Qrumpharma Inc  
Quratis Inc  
QureTech Bio AB  
Qurient Co Ltd  
Sanofi  
Sequella Inc  
Serum Institute of India Ltd  
Shanghai H&G Biotech  
Shanghai Jiatan Pharmaceutical Technology Co Ltd  
Shionogi & Co Ltd  
Spero Therapeutics Inc  
Sphaera Pharma Pte Ltd  
Takeda Pharmaceutical Co Ltd  
Target Medicals LLC  
TB-Stopper  
TenNor Therapeutics Ltd  
The Broad Institute Inc  
Theravectys SA  
TVAX Biomedical Inc  
Tydock Pharma Srl  
Vaccibody AS  
Vaxil Bio Therapeutics Ltd  
Vaxinano SE  
Vaxine Pty Ltd  
Vaxxit Srl  
Vichem Chemie Research Ltd  
Vir Biotechnology Inc  
Zata Pharmaceuticals Inc

## I would like to order

Product name: Tuberculosis - Pipeline Review, H1 2020

Product link: <https://marketpublishers.com/r/T933ED09586EN.html>

Price: US\$ 2,000.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/T933ED09586EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970